Patents by Inventor Chandreshwar Prasad Shukla

Chandreshwar Prasad Shukla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic cancer vaccine
    Patent number: 11219674
    Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: January 11, 2022
    Assignee: Cadila Pharmaceuticals Ltd.
    Inventors: Bakulesh Mafatlal Khamar, Nirav Manojkumar Desai, Chandreshwar Prasad Shukla, Avani Devenbhai Darji, Indravadan Ambalal Modi
  • Therapeutic Cancer Vaccine
    Publication number: 20190262443
    Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 29, 2019
    Applicant: Cadila Pharmaceuticals Ltd.
    Inventors: Bakulesh Mafatlal Khamar, Nirav Manojkumar Desai, Chandreshwar Prasad Shukla, Avani Devenbhai Darji, Indravadan Ambalal Modi
  • Therapeutic cancer vaccine
    Patent number: 10335472
    Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: July 2, 2019
    Assignee: Cadila Pharmaceuticals Ltd.
    Inventors: Bakulesh Mafatlal Khamar, Nirav Manojkumar Desai, Chandreshwar Prasad Shukla, Avani Devenbhai Darji, Indravadan Ambalal Modi
  • Cancer antigen
    Patent number: 9714275
    Abstract: Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to cancer cells (homologue and hetrologus) of tissue/organ of origin. The immune response generated by administration of commonly expressed or over expressed antigen not reactive to normal cells and cancer cells or different tissue/organ of origin.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: July 25, 2017
    Assignee: Cadila Pharmaceuticals Ltd.
    Inventors: Indravadan Ambalal Modi, Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar, Chandreshwar Prasad Shukla, Vipul Sitaram Thakkar, Nirav Manojkumar Desai
  • Therapeutic Cancer Vaccine
    Publication number: 20170157231
    Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.
    Type: Application
    Filed: January 20, 2017
    Publication date: June 8, 2017
    Inventors: Bakulesh Mafatlal Khamar, Nirav Manojkumar Desai, Chandreshwar Prasad Shukla, Avani Devenbhai Darji, lndravadan Ambalal Modi
  • CANCER ANTIGEN
    Publication number: 20140294896
    Abstract: Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to cancer cells (homologue and hetrologus) of tissue/organ of origin. The immune response generated by administration of commonly expressed or over expressed antigen not reactive to normal cells and cancer cells or different tissue/organ of origin.
    Type: Application
    Filed: July 4, 2012
    Publication date: October 2, 2014
    Inventors: Indravadan Ambalal Modi, Bakulesh Mafatlal Khamar, Chandreshwar Prasad Shukla, Vipul Sitaram Thakkar, Nirav Manojkumar Desai
  • Therapeutic Cancer Vaccine
    Publication number: 20130330375
    Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.
    Type: Application
    Filed: February 27, 2012
    Publication date: December 12, 2013
    Applicant: Cadila Pharmaceuticals Limited
    Inventors: Bakulesh Mafatlal Khamar, Nirav Manojkumar Desai, Chandreshwar Prasad Shukla, Avani Devenbhai Darji, Indravadan Ambalal Modi